{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:26:35Z","timestamp":1772598395537,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T00:00:00Z","timestamp":1361491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00702-013-0994-0","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T16:44:06Z","timestamp":1361465046000},"page":"649-653","source":"Crossref","is-referenced-by-count":29,"title":["The practical management of cognitive impairment and psychosis in the older Parkinson\u2019s disease patient"],"prefix":"10.1007","volume":"120","author":[{"given":"John V.","family":"Hindle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,22]]},"reference":[{"issue":"10","key":"994_CR1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord 20(10):1255\u20131263","journal-title":"Mov Disord"},{"key":"994_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z et al (2009) Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies a double-blind, placebo-controlled multicentre trial. Lancet Neurol 8:613\u2013618","journal-title":"Lancet Neurol"},{"issue":"6","key":"994_CR3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1368-5031.2006.00967.x","volume":"60","author":"C Ballard","year":"2006","unstructured":"Ballard C, Lane R, Barone P, Ferrara R, Tekin S (2006) Cardiac safety of rivastigmine in Lewy body and Parkinson\u2019s disease dementias. Int J Clin Pract 60(6):639\u2013645","journal-title":"Int J Clin Pract"},{"issue":"2","key":"994_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pnp.231","volume":"16","author":"S Bleakley","year":"2012","unstructured":"Bleakley S (2012) Identifying and reducing the risk of antipsychotic drug interactions. Prog Neurol Psychiatry 16(2):20\u201324","journal-title":"Prog Neurol Psychiatry"},{"key":"994_CR5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","volume":"60","author":"NI Bohnen","year":"2003","unstructured":"Bohnen NI, Kaufer DI, Ivanco LS et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745\u20131748","journal-title":"Arch Neurol"},{"issue":"11","key":"994_CR6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D, Emre M, McKeith I et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord 21(11):1899\u20131907","journal-title":"Mov Disord"},{"key":"994_CR7","unstructured":"Cochrane Database of Systematic Reviews (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease, Issue 3. Art.No.: CD006504"},{"issue":"16","key":"994_CR8","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder task force. Mov Disord 22(16):2314\u20132324","journal-title":"Mov Disord"},{"key":"994_CR9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonucelli U et al (2010) Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, pacebo-controlled trial. Lancet Neurol 9:969\u2013977","journal-title":"Lancet Neurol"},{"key":"994_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjopharm.2010.08.004","volume":"8","author":"ML Eng","year":"2010","unstructured":"Eng ML, Welty TE (2010) Management of hallucinations and psychosis in Parkinson\u2019s disease. Am J Geriatr Pharmacother 8:316\u2013330","journal-title":"Am J Geriatr Pharmacother"},{"issue":"8","key":"994_CR11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T et al (2010) A 12-year population-based study of psychosis in Parkinson\u2019s disease. Arch Neurol 67(8):996\u20131001","journal-title":"Arch Neurol"},{"issue":"9","key":"994_CR12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"SS Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD et al (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Int Med 169(9):867\u2013873","journal-title":"Arch Int Med"},{"issue":"6","key":"994_CR13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20\u00a0years. Mov Disord 23(6):837\u2013844","journal-title":"Mov Disord"},{"key":"994_CR14","unstructured":"Hindle JV (2008) Neuropsychiatry. In: Playfer J, Hindle J (eds) Parkinson\u2019s disease in the older patient, 2nd edn. Radcliffe. ISBN-13:978184619 114 5"},{"issue":"2","key":"994_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ageing\/afp223","volume":"39","author":"JV Hindle","year":"2010","unstructured":"Hindle JV (2010) Ageing, neurodegeneration and Parkinson\u2019s disease. Age Ageing 39(2):156\u2013161","journal-title":"Age Ageing"},{"key":"994_CR16","doi-asserted-by":"crossref","unstructured":"Hindle JV, Petrelli A, Clare L, Kalbe E (2013) Non-pharmacological enhancement of cognitive function in Parkinson\u2019s disease: a systematic review. Mov Disord (in press)","DOI":"10.1002\/mds.25377"},{"key":"994_CR17","doi-asserted-by":"crossref","unstructured":"Hobson P, Meara J, Ishihara-Paul L (2010) The estimated life expectancy in a community cohort of Parkinson\u2019s disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry 81:1093e1098","DOI":"10.1136\/jnnp.2009.198689"},{"issue":"3","key":"994_CR18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1532-5415.2011.03853.x","volume":"60","author":"KF Huybrechts","year":"2012","unstructured":"Huybrechts KF, Schneeweis F, Gerhard T et al (2012a) Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 60(3):420\u2013429","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"994_CR19","first-page":"420","volume":"60","author":"KF Huybrechts","year":"2012","unstructured":"Huybrechts KF, Gerhard T, Crystal S et al (2012b) Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 60(3):420\u2013429","journal-title":"BMJ"},{"issue":"6","key":"994_CR20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","volume":"59","author":"DH Kim","year":"2011","unstructured":"Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 59(6):1019\u20131031","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"994_CR21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpsychores.2008.05.026","volume":"65","author":"JV Laurila","year":"2008","unstructured":"Laurila JV, Laakkononen ML, Tilvis RS, Pitkala KH (2008) Predisposing factors for delirium in a frail geriatric population. J Psychosom Res 65(3):249\u2013254","journal-title":"J Psychosom Res"},{"issue":"8","key":"994_CR22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","volume":"24","author":"I Leroi","year":"2009","unstructured":"Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A (2009) Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease. Mov Disord 24(8):1217\u20131221","journal-title":"Mov Disord"},{"issue":"1","key":"994_CR23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mppsy.2007.11.004","volume":"7","author":"ER Marcantonio","year":"2007","unstructured":"Marcantonio ER (2007) Clinical management and prevention of delirium. Psychiatry 7(1):42\u201348","journal-title":"Psychiatry"},{"key":"994_CR24","unstructured":"Martindale: the complete drug reference (2011) 37th edition. Pharmaceutical Press. ISBN-978 0 85369 933 0"},{"key":"994_CR25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","volume":"58","author":"M Murray","year":"2006","unstructured":"Murray M (2006) Role of CYP pharmacogenetics and drug\u2013drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58:871\u2013885","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"994_CR26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3109\/15622975.2010.488273","volume":"11","author":"DW O\u2019Connor","year":"2010","unstructured":"O\u2019Connor DW, Sierakowski C, Chin LF, Singh D (2010) The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry 11(6):788\u2013791","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"994_CR27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12012-010-9088-5","volume":"10","author":"B Paulison","year":"2010","unstructured":"Paulison B, L\u00e9os CL (2010) Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. Cardiovasc Toxicol 10(4):306\u2013310","journal-title":"Cardiovasc Toxicol"},{"issue":"Suppl 17","key":"994_CR28","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1002\/mds.21681","volume":"22","author":"W Poewe","year":"2007","unstructured":"Poewe W (2007) Dysautonomia and cognitive dysfunction in Parkinson\u2019s disease. Mov Disord 22(Suppl 17):S374\u2013S378","journal-title":"Mov Disord"},{"key":"994_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1192\/apt.bp.106.002725","volume":"13","author":"JP Rowland","year":"2007","unstructured":"Rowland JP, Rigby J, Harper AC et al (2007) Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat 13:178\u2013184","journal-title":"Adv Psychiatr Treat"},{"issue":"6","key":"994_CR30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.parkreldis.2005.05.002","volume":"11","author":"M Serrano-Due\u00f1as","year":"2005","unstructured":"Serrano-Due\u00f1as M, Bleda MJ (2005) Delirium in Parkinson\u2019s disease patients: a five year follow up study. Parkinsonism Relat Disord 11(6):387\u2013392","journal-title":"Parkinsonism Relat Disord"},{"key":"994_CR31","doi-asserted-by":"crossref","unstructured":"Taylor JP, Rowan EN, Lett D, O\u2019Brien JT, McKeith IG, Burn DJ (2008) Poor attentional function predicts cognitive decline in patients with non-demented Parkinson\u2019s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry. 79(12):1318\u20131323 [Epub 2008 Jun 27]","DOI":"10.1136\/jnnp.2008.147629"},{"key":"994_CR32","volume-title":"The Maudsley prescribing guidelines","author":"D Taylor","year":"2010","unstructured":"Taylor D, Paton C, Kapur S (2010) The Maudsley prescribing guidelines, 10th edn. Informa Healthcare, London","edition":"10"},{"key":"994_CR33","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(10)61855-7","volume":"376","author":"MMJ Eijk van","year":"2010","unstructured":"van Eijk MMJ, Roes KC, Honing ML et al (2010) Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 376:1829\u20131837","journal-title":"Lancet"},{"key":"994_CR34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","volume":"17","author":"T Laar van","year":"2011","unstructured":"van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE (2011) Effects of cholinesterase inhibitors in Parkinson\u2019s disease dementia: a review of clinical data. CNS Neurosci Ther 17:428\u2013441","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"994_CR35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011a) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68(7):899\u2013904","journal-title":"Arch Neurol"},{"issue":"6","key":"994_CR36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1533317511424892","volume":"26","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Somogyi M, Meng X (2011b) Rivastigmine in Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: an ADAS-Cog factor analysis. Am J Alzheimers Dis Other Demen 26(6):443\u2013449","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"Pt 7","key":"994_CR37","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","volume":"130","author":"CH Williams-Gray","year":"2007","unstructured":"Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort. Brain 130(Pt 7):1787\u20131798","journal-title":"Brain"},{"issue":"14","key":"994_CR38","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/mds.23932","volume":"26","author":"A Yarnall","year":"2011","unstructured":"Yarnall A, Rochester L, Burn D (2011) The interplay of cholinergic function, attention and falls in Parkinson\u2019s disease. Mov Disord 26(14):2496\u20132503","journal-title":"Mov Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-0994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0994-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:24:04Z","timestamp":1562718244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-0994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,22]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-0994-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,22]]}}}